Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

Benzinga · 3d ago
Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.